



ipgroup

IP GROUP'S CORE PURPOSE IS TO **EVOLVE GREAT IDEAS INTO WORLD-CHANGING BUSINESSES** THAT WILL HAVE A POSITIVE IMPACT ON THE WORLD

Through the businesses that we back and build, we aim to address some of the world's most pressing challenges in areas such as disease prevention, transitioning to a less carbon intense energy world, and productivity improvement. Our team has spent many years finessing its approach to identify attractive intellectual property, nurture & build companies, and provide capital and support from "cradle to maturity". We have also sought to adopt this approach with research institutions in the US and Australia.

OUR STRATEGIC AIMS



To **create** and maintain a pipeline of compelling intellectual property-based opportunities



To **develop** and support these opportunities into a diversified portfolio of robust businesses



To **deliver** attractive financial returns on our assets and third party funds



reprogramming metabolism to treat autoimmune and inflammatory conditions



Enabling DNA analysis by anyone anywhere



Steel fuel cells for cheaper, cleaner, distributed power generation



Creating the sense of touch in thin air



Making fusion energy a reality

FEATURE SPACE

Adaptive Behavioural Analytics for real time fraud detection

IP GROUP PLC LEADERSHIP



Sir Douglas Flint
Chairman

Former Group Chairman of HSBC Holdings plc, former Group Finance Director of HSBC. Former partner of KPMG. Former Non-Executive Director of BP plc.

Chairman of the Corporate Board of Cancer Research UK, Trustee of the Royal Marsden Cancer Charity.


Alan Aubrey
Chief Executive Officer

Corporate finance background (partner KPMG) Deep expertise of building technology businesses


Co-founder Techtran Group Ltd; bought by IP Group plc




IP GROUP AT A GLANCE



Fair value by sector



Fair value by focus



SUPPORTING SUSTAINABLE DEVELOPMENT

| | THEMATIC FOCUS | PORTFOLIO COMPANY | SDG TARGET | SUSTAINABLE DEVELOPMENT GOALS |
|---------------|---|--|---|---|
| TECHNOLOGY | DATA ANALYTICS | AMSL Innovations Featurespace Garrison Technology Helio Display Materials | 11.2 Affordable and sustainable transport systems 11.3 Inclusive & sustainable urbanisation 11.6 Reduce the environmental impact of cities | 11 SUSTAINABLE CITIES AND COMMUNITIES |
| | CYBER DEFENCE IT TO IMPROVE EFFICIENCY | Mixergy Oxbotica | 9.1 Develop sustainable, resilient & inclusive infrastructures 9.4 Upgrade all industries and infrastructures for sustainability 9.5 Enhance research and upgrade industrial technologies 9.C Universal access to ICT | 9 INDUSTRY INNOVATION AND INFRASTRUCTURE |
| CLEANTECH | RENEWABLE ENERGY | Azuri Technologies Bramble Energy C-Capture Ceres Power Holdings Econic Technologies First Light Fusion Mixergy | 7.1 Universal access to modern energy 7.2 Increase global percentage of renewable energy 7.3 Double energy efficiency 7.A Promote R&D and investment into cleantech 7.B Expand & upgrade energy services in developing countries | 7 AFFORDABLE AND CLEAN ENERGY |
| | SUSTAINABLE TRANSPORT | Mixergy Oxbotica Oxford Nanopore Technologies RFC Power | 13.2 Integrate climate change measures into policies & planning 13.3 Build knowledge & capacity to meet climate change | 13 CLIMATE ACTION |
| | ENERGY TRANSITION | Azuri Technologies Econic Technologies Mixergy | 12.2 By 2030, achieve the sustainable management and efficient use of natural resources 12.4 Achieve the environmentally sound management of chemicals and all wastes throughout their life cycle | 12 RESPONSIBLE CONSUMPTION AND PRODUCTION |
| LIFE SCIENCES | DIAGNOSTICS THERAPEUTICS ONCOLOGY DIGITAL HEALTH | Artios Pharma Cell Medica Creavo Medical Tech Crescendo Biologics Diurnal Group Enterprise Therapeutics Genomics Ieso Digital Health Iksuda Therapeutics Invata Istesso Mission Therapeutics MOBILion Oxehealth Oxford Nanopore Technologies Oxular PsiOxus Threapeutics | 3.3 By 2030, end the epidemics of AIDS, tuberculosis, malaria and neglected tropical diseases and combat hepatitis, water-borne diseases and other communicable diseases 3.4 By 2030, reduce by one third premature mortality from non-communicable diseases and promote mental health and well being 3.D Strengthen the capacity for early warning, risk reduction and management of national and global health risks. | 3 GOOD HEALTH AND WELL-BEING |

SUSTAINABLE DEVELOPMENT GOAL

www.ipgroupplc.com
Stock code (LSE): IPO

Numbers as at 31 December 2019